Posted 1/4/2024, 10:50:18 PM
Moderna Stock Outperforms Broader Markets as Analysts Remain Optimistic Despite Expected Revenue Decline
- Moderna (MRNA) stock price closed up 0.07% while broader markets fell
- MRNA stock up 34.72% over past month, outpacing medical sector and S&P 500
- MRNA projected to report $2.35B in revenue this quarter, a 53.76% year-over-year decline
- Positive estimate revisions signal analyst optimism about MRNA's business
- MRNA currently has a Zacks Rank of #3 (Hold) in the Medical - Biomedical and Genetics industry, a top 30% industry